{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-26-000040","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-06-24T20:10:12+00:00","discovered_at":"2026-06-24T20:11:00.306658+00:00","generated_at":"2026-06-24T20:11:27.849002+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Serina increases authorized common stock from 40M to 125M; equity plan expanded by 2M shares","bullets":["Authorized common stock increased from 40,000,000 to 125,000,000 shares via filed certificate of amendment.","2024 Equity Incentive Plan share reserve raised by 2,000,000 shares to 5,210,478; evergreen start moved to FY2027.","Stockholders approved all eight proposals at annual meeting, including director elections and share increase."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-26-000040","json":"https://secwatch.observer/filing/0001708599-26-000040.json","markdown":"https://secwatch.observer/filing/0001708599-26-000040.md","text":"https://secwatch.observer/filing/0001708599-26-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000040/0001708599-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000040/ser-20260617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T20:11:27.849002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}